Bladder cancer is one of the most predominant tumors of the genitourinary tract. In addition to pathological findings, the molecular modifications that might affect tumorigenesis and tumor outcome should be considered when treating bladder cancer. Accordingly, we aimed to investigate the expression levels of both the ASPM and TEF genes in bladder cancer tissues and their value in disease prognosis. The expression levels of the ASPM and TEF genes were analyzed by quantitative real-time PCR (qRT-PCR) in 90 bladder cancer tissue specimens and 90 specimens of normal urinary bladder tissue taken away from the tumor site. The upregulation of ASPM expression and the downregulation of TEF expression were observed in bladder cancer tissues compared to adjacent normal tissues, and these levels were correlated with high-grade tumors, advanced stage disease and the presence of metastasis. Both genes had the ability to predict metastatic association with sensitivity (84.62%) and specificity (68.42%; *P < 0.001) for the ASPM gene and for the TEF gene with sensitivity (80.77%) and specificity (78.95%; *P < 0.001). Additionally, Kaplan–Meier survival analysis indicated that elevated ASPM expression levels and reduced TEF expression levels significantly correlated with decreased overall survival and progression-free survival. The current analysis concludes that ASPM and TEF expressions might be used as potential biomarkers in bladder cancer patients.

中文翻译：

---

评价ASPM和TEF基因表达作为膀胱癌的潜在生物标志物。

膀胱癌是泌尿生殖道最主要的肿瘤之一。除病理学发现外，治疗膀胱癌时应考虑可能影响肿瘤发生和肿瘤预后的分子修饰。因此，我们旨在研究ASPM和TEF基因在膀胱癌组织中的表达水平及其在疾病预后中的价值。所述的表达水平ASPM和TEF基因通过定量实时PCR（QRT-PCR）在90膀胱癌组织标本进行分析，并从肿瘤部位带走90例正常膀胱组织。ASPM表达的上调和TEF的下调与邻近的正常组织相比，在膀胱癌组织中观察到其表达，且这些水平与高级别肿瘤，晚期疾病和转移的存在相关。这两个基因都具有预测转移相关性的能力，对于ASPM基因和TEF基因的敏感性（84.62％）和特异性（68.42％; * P <0.001）和敏感性（80.77％）和特异性（78.95％; * P < 0.001）。0.001）。此外，Kaplan–Meier生存分析表明，ASPM表达水平升高和TEF表达水平降低与总体生存率降低和无进展生存率显着相关。当前的分析得出结论，ASPM和TEF 表达可能被用作膀胱癌患者的潜在生物标志物。